Multi-year program supports development of disposable molecular diagnostic platforms for point-of-care, field-use, and emergency response settings

多年期计划支持开发用于即时检测、现场使用和应急响应场景的一次性分子诊断平台

BOSTON

波士顿

,

，

July 14, 2026

2026年7月14日

/PRNewswire/ -- Sapphiros today announced it has been awarded a multi-year project agreement through the Rapid Response Partnership Vehicle (RRPV), to advance rapid, portable, connected, molecular diagnostic platforms for detection of biothreats and emerging infectious diseases.

/美通社/ -- Sapphiros 今日宣布，公司已通过快速响应合作伙伴关系工具（RRPV）获得一项多年期项目协议，旨在推进用于检测生物威胁和新发传染病的快速、便携式、联网分子诊断平台的发展。

RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

RRPV 是由美国卫生与公众服务部（HHS）下属战略准备与响应管理局（ASPR）内的生物医学高级研究与开发局（BARDA）资助的联盟。

The agreement includes a 24-month base period to support the continued development of Sapphiros' proprietary molecular diagnostics platform, with a focus on enabling rapid  detection of priority biothreat pathogens  in point-of-care and

该协议包括一个24个月的基础期，以支持Sapphiros专有分子诊断平台的持续开发，重点在于实现优先生物威胁病原体在即时检测（POCT）中的快速检测

decentralized

去中心化的

settings.

设置。

The  program is designed to advance disposable molecular testing capabilities for blood-based pathogens that can deliver laboratory-quality results through a simple, automated workflow. To ensure biosafety, the Sapphiros molecular device utilizes a novel, closed blood collection tube that eliminates the risk of blood-borne contamination during sample transfer to the device..

该计划旨在提升针对血液传播病原体的即时分子检测能力，通过简单、自动化的工作流程提供实验室级别的检测结果。为确保生物安全，Sapphiros 分子检测设备采用了一种新型封闭式采血管，消除了样本转移至设备过程中血源性污染的风险。

The program leverages Satio's integrated capillary blood collection system to facilitate phlebotomist-free blood collection at the point of need. Satio, has developed a single use collection device equipped with an integrated safety lancet, designed to minimize user handling and biohazard exposure while ensuring consistent sample volumes for reliable testing in emergency response and field settings..

该计划利用 Satio 的集成毛细管血液采集系统，以便在需求点实现无需采血师的血液采集。Satio 开发了一种一次性采集装置，配备集成式安全采血针，旨在最大限度地减少用户操作和生物危害暴露，同时确保样本体积一致，从而在应急响应和现场环境中提供可靠的检测结果。

'Our program reflects the urgent need for diagnostic technologies that can move quickly from outbreak recognition to field deployment,' said Mark Gladwell, CEO of Sapphiros. 'By combining  connected, disposable molecular platform and innovative blood collection approach, we aim to deliver rapid, reliable testing solutions that can support clinicians, public health responders and communities during biological threats and emerging health emergencies.'.

“我们的项目反映了对诊断技术的迫切需求，这些技术能够迅速从疫情识别过渡到实地部署，”Sapphiros公司首席执行官马克·格拉德韦尔表示。“通过将互联式一次性分子平台与创新的血液采集方法相结合，我们旨在提供快速、可靠的检测解决方案，以在生物威胁和新发卫生紧急事件期间支持临床医生、公共卫生响应人员以及社区。”

This funding marks Sapphiros' second agreement with BARDA, following the previously announced agreement to develop an over-the-counter, single use low-cost digital antigen test capable of detecting and differentiating respiratory viruses.

这笔资金标志着Sapphiros与BARDA达成的第二项协议，此前已宣布一项协议，旨在开发一种非处方、一次性、低成本的数字抗原检测产品，能够检测并区分呼吸道病毒。

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005.

本项目全部或部分由美国卫生与公众服务部、战略准备与响应管理局（ASPR）以及生物医学高级研究与发展管理局（BARDA）提供的联邦资金资助，其他交易编号为：75A50123D00005。

About Sapphiros

关于萨菲罗斯

Sapphiros, backed by KKR and Neoenta, is a privately held consumer diagnostics company shaping the future of consumer and public health diagnostics by developing accessible, affordable and scalable health technologies. The company brings together advanced science, intelligent design and scalable manufacturing to make high-quality diagnostic testing more broadly available.

Sapphiros 由 KKR 和 Neoenta 支持，是一家私营消费级诊断公司，通过开发可及、 affordable 且可扩展的健康技术，塑造消费级与公共健康诊断的未来。该公司融合先进科学、智能设计与规模化制造，使高质量诊断检测更广泛地惠及大众。

Sapphiros' portfolio spans sample collection, next-generation diagnostics and extreme-volume manufacturing capabilities designed to deliver fast, accurate results across a wide range of health needs..

Sapphiros 的业务组合涵盖样本采集、下一代诊断技术以及超大规模制造能力，旨在为广泛的健康需求提供快速、准确的结果。

For Media Relations email

媒体联络邮箱

[email protected]

[email protected]

SOURCE Sapphiros

来源：萨菲罗斯

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量与

Request a Demo

申请演示